Real-time enrollment status for this cerebral amyloid angiopathy clinical trial
Current Status
Recruiting
Checked: July 17, 2026 at 7:47 PM UTC
| NCT Number | NCT06393712 |
| Recruiting Status | Recruiting |
| Condition | Cerebral Amyloid Angiopathy |
| Phase | PHASE2 |
| Target Enrollment | 200 participants |
| Active Locations | 34 sites in the US |
| Sponsor | Alnylam Pharmaceuticals |
| Last Updated on CT.gov | July 15, 2026 (2 days ago) |
As of July 17, 2026: Clinical trial NCT06393712 is currently recruiting participants. This phase2 study for cerebral amyloid angiopathy is actively seeking new participants at 34 locations across the United States. The study is sponsored by Alnylam Pharmaceuticals. This status information is automatically verified from the official ClinicalTrials.gov registry.
Yes, NCT06393712 is actively recruiting participants as of July 17, 2026. You can check eligibility and apply through HelloStudys.
This trial is recruiting at 34 locations in the United States. View all available locations on the full study page.
Check your eligibility and express interest by completing the application form on the study page. A research coordinator will follow up to discuss next steps.
The official ClinicalTrials.gov record for NCT06393712 was last updated 2 days ago (July 15, 2026). HelloStudys verifies this status automatically.